Genome mining discovers ruskamycin, a glycosylated griseorhodin, showing antibacterial activity in Gram-positive strains, suggesting potential therapeutic use.
, predicted to enable the biosynthesis of a glycosylated griseorhodin variant. Following the successful cultivation of the strain, the production of a previously uncharacterized griseorhodin, named ruskamycin, was confirmed that featured a distinctive digitoxose-substituted epoxy-spiroketal pharmacophore and exhibited antibacterial activity against Gram-positive strains.
No takes yet. Share an insight, caveat, or question.
Sowa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: